Admedus adopts cloud-based platform for genital herpes vaccine trial
The Australian-based company hopes to use the platform to improve the speed, efficiency and decision-making process for the vaccine, which is meant to provoke a response from T-cells against the herpes virus.
”It is estimated that up to 20 million people worldwide are newly infected with HSV-2 each year,” Admedus CEO Lee Rodne said. “Our potential therapeutic vaccine could have life-changing effects for these people and future generations. Admedus’ study is currently progressing well and we are expecting some interim results from our Phase II clinical trial later this year.”
The research will benefit herpes patients around the world.
“We’re excited to be working alongside such a forward-thinking organization as Admedus, especially as we expand into the clinical trial landscape in Australia,” Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific region, said. “We share Admedus’ mission of making a difference in the outcomes and quality of life for patients — both in Australia and around the globe — and are proud to power their research as they continue to develop innovative immunotherapies to help treat and prevent infectious diseases.”